Drug intelligence / Profile preview

NCP111

Development stage: Preclinical
Lead developer: NovaCell Technology
Modality: Small Molecules, Peptides

Overview

NCP111 is a synthetic peptide drug candidate developed by Novacell Technology for the treatment of asthma. It acts as a modulator of formyl peptide receptors FPR1 and FPR2, which are G protein-coupled receptors involved in immune cell chemotaxis and inflammation. By targeting these receptors, NCP111 aims to reduce airway inflammation and bronchoconstriction associated with asthma. The drug is currently in preclinical development.

Targets

FPR1 (Formyl peptide receptor 1)FPR2 (Formyl peptide receptor type 2)

Beyond the preview

Go deeper on NCP111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NCP111.

Explore the full profile